- Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2012 - Conditions: Alloantibodies; Heart Transplantation; Immunologic Memory
Intervention: Drug: Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis (Multidrug Protocol)
Sponsors: Providence Health & Services; Providence Health & Services
Not yet recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Peripheral Neuropathies; Multiple Myeloma
Intervention: Device: Acupuncture
Sponsors: University of Maryland; University of Maryland
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Intervention: Drug: G-CSF and Bortezomib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Other: pharmacological study; Drug: tacrolimus; Drug: sirolimus; Biological: anti-thymocyte globulin; Drug: fludarabine phosphate; Drug: busulfan; Drug: bortezomib; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia
Intervention: Drug: sorafenib, vorinostat and bortezomib
Sponsors: Indiana University; Indiana University; Millennium Pharmaceuticals, Inc.; Bayer; Merck
Recruiting - verified February 2012 - Condition: Waldenstrom Macroglobulinemia
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: TH-302; Drug: TH-302; Drug: TH-302 and bortezomib
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation; Multiple Myeloma Research Consortium
Recruiting - verified April 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: Lapatinib and bortezomib
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Sponsors: Duke University; Duke University; Spectrum Pharmaceuticals, Inc
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention: Drug: Panitumumab and bortezomib
Sponsors: Georgetown University; Georgetown University; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Ganetespib Dexamethasone; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: masitinib 6 mg/kg/day; Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified November 2011 - Condition: Multiple Myeloma
Intervention: Drug: Fludarabine monophosphate, melphalan, Bortezomib
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified October 2011 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
Intervention: Drug: bortezomib
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Temozolomide, bevacizumab and bortezomib
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Procedure: Blood draws
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Drug: bortezomib; Drug: decitabine
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab; Drug: bortezomib; Drug: Cladribine
Sponsors: Penn State University; Penn State University
Not yet recruiting - verified September 2011 - Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)Condition: Mantle Cell Lymphoma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Georgia Health Sciences University; Anand Jillella; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: proteasome inhibitor MLN9708; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Procedure: biopsy; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Other: flow cytometry
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Melphalan; Drug: Bortezomib
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified October 2011 - Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Cognitive/Functional Effects; Fatigue; Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bortezomib; Drug: dexamethasone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Group A: Carfilzomib & Non-IMiD Regimen; Drug: Group B: Carfilzomib & IMiD containing regimen.
Sponsors: Oncotherapeutics; Oncotherapeutics; Onyx Pharmaceuticals
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Conditions: Disorder of Transplanted Kidney; Donor Specific Alloantibodies
Interventions: Drug: Bortezomib; Other: Standard posttransplant treatment
Sponsors: Mayo Clinic; Mayo Clinic; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Myelodysplastic Syndrome
Intervention: Drug: Bortezomib, Tacrolimus, Methotrexate
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2011 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib
Sponsors: New York University School of Medicine; New York University School of Medicine; Cephalon
Recruiting - verified March 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib; Drug: Vorinostat; Drug: Dexamethasone; Drug: Methotrexate; Drug: Imatinib mesylate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade; Drug: Temsirolimus
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Millennium Pharmaceuticals, Inc.; Pfizer
Recruiting - verified December 2011 - Condition: Myeloma
Interventions: Other: Placebo; Drug: Minocycline
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib; Biological: rituximab; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: DNA analysis; Other: pharmacological study; Other: pharmacogenomic studies
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University of Arkansas; University of Arkansas; National Institutes of Health (NIH)
Recruiting - verified March 2012 - Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011 - Condition: Multiple Myeloma
Intervention: Drug: Thalidomide+Melphalan +Bortezomib+stem cell tranplant
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011 - Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis; Other: gene expression analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011 - Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Fludarabine; Drug: Velcade; Drug: Rituximab
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Genentech; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Multiple Myeloma; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Intervention: Drug: AT7519M, Bortezomib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals; Multiple Myeloma Research Consortium
Recruiting - verified July 2011 - Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Doxorubicin; Drug: Bortezomib; Drug: Bendamustine; Drug: Filgrastim
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Cephalon
Recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
Interventions: Drug: midostaurin, bortezomib,; Drug: mitoxantrone hydrochloride, etoposide, cytarabine, midostaurin, bortezomib
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Novartis; Millennium Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Conditions: Malignant Lymphoma, Stem Cell Type; Autologous Transplant
Intervention: Drug: bortezomib and G-CSF
Sponsors: University of Kansas; University of Kansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma
Interventions: Drug: bortezomib; Drug: fludarabine phosphate; Other: melphalan; Radiation: intensity-modulated radiation therapy; Radiation: total marrow irradiation; Radiation: tomotherapy; Drug: tacrolimus; Drug: sirolimus
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Condition: Bronchiolitis Obliterans
Intervention: Drug: Bortezomib
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified May 2012 - Condition: Chronic Graft vs Host Disease
Intervention: Drug: bortezomib
Sponsors: Baylor Research Institute; Baylor Research Institute; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Advanced Cancer
Intervention: Drug: FLT-PET
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaConditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: bortezomib; Drug: mitoxantrone hydrochloride; Drug: etoposide; Drug: cytarabine; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Prolymphocytic Leukemia; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Small Intestine Lymphoma; T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: azacitidine; Drug: bortezomib; Other: laboratory biomarker analysis; Other: pharmacological study; Genetic: protein expression analysis; Genetic: gene expression analysis; Genetic: DNA methylation analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Genetic: microarray analysis; Other: enzyme-linked immunosorbent assay; Other: liquid chromatography; Other: mass spectrometry; Genetic: reverse transcriptase-polymerase chain reaction
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Millennium Pharmaceuticals, Inc.; Celgene Corporation
Recruiting - verified November 2011 - Condition: Lymphoma, Non-Hodgkins
Intervention: Drug: Ofatumumab and Bortezomib
Sponsors: Brown University; Debora G. Isdale; Rhode Island Hospital; The Miriam Hospital; Memorial Hospital of Rhode Island
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Chronic Kidney Disease; IgA Nephropathy
Intervention: Drug: Bortezomib (Velcade®)
Sponsors: The Rogosin Institute; The Rogosin Institute; Weill Medical College of Cornell University
Recruiting - verified April 2012 - Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: velcade, sorabenib
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Everolimus; Drug: Rituximab; Drug: Bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab; Drug: Fludarabine; Drug: Everolimus; Drug: Bortezomib; Drug: Chlorambucil
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Melanoma
Interventions: Drug: bortezomib; Drug: sorafenib
Sponsors: Dana-Farber Cancer Institute; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Isreal Deaconess Medical Center; Brigham and Women's Hospital; Bayer; Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: bortezomib; Drug: carboplatin; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib; Drug: belinostat; Other: laboratory biomarker analysis; Genetic: western blotting; Other: pharmacological study; Other: flow cytometry
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified March 2012 - Conditions: Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections
Interventions: Drug: bortezomib; Drug: rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: Aurora A kinase inhibitor MLN8237; Drug: bortezomib
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Rituximab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Cephalon
Recruiting - verified July 2011 - Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Breast Cancer; Colorectal Cancer; Myeloma; Chemotherapy-induced Peripheral Neuropathy
Interventions: Behavioral: Questionnaire; Behavioral: Sensory Tests; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
Sponsors: Boston Medical Center; Boston Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2011 - Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: bortezomib + Temozolomide; Radiation: external beam radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Conditions: Anaplastic Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: rituximab; Drug: carmustine; Drug: cytarabine; Drug: etoposide; Drug: melphalan; Drug: bortezomib; Drug: vorinostat; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; B-cell Lymphoma
Intervention: Drug: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Sponsors: University of California, San Francisco; University of California, San Francisco; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Conditions: Cancer; Myeloma; Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University of Utah; University of Utah; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Drug: rituximab; Drug: bortezomib; Drug: cladribine
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Leukemia; Lymphoma
Interventions: Drug: Bortezomib; Drug: Romidepsin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Mantle Cell Lymphoma; Lymphoma
Interventions: Drug: Bortezomib; Drug: Rituximab; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Melphalan; Procedure: Autologous Stem Cell Transplant; Drug: Bortezomib; Drug: Fludarabine; Drug: Melphalan
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012 - Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100); Drug: bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Genzyme
Recruiting - verified May 2012 - Condition: Advanced Cancers
Intervention: Drug: Erlotinib Hydrochloride (Tarceva)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Erlotinib Hydrochloride; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (Velcade); Drug: Panobinostat
Sponsors: University of Utah; University of Utah; Novartis
Recruiting - verified January 2012 - Conditions: Lymphoma; Myeloma; Peripheral Neuropathy
Intervention: Other: Acupuncture
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012 - Condition: Myeloma
Intervention: Drug: Velcade
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: gemcitabine hydrochloride
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: bortezomib; Drug: vorinostat
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: bortezomib; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Merck; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation; Drug: bortezomib; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Other: flow cytometry; Other: laboratory biomarker analysis; Drug: melphalan; Procedure: peripheral blood stem cell transplantation; Genetic: fluorescence in situ hybridization; Drug: cyclosporine; Procedure: autologous hematopoietic stem cell transplantation; Procedure: syngeneic bone marrow transplantation; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Advanced Cancer
Interventions: Drug: Torisel (Temsirolimus); Drug: Hycamtin (Topotecan); Drug: Velcade (Bortezomib)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Kidney Transplant
Intervention: Drug: Bortezomib
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012 - Conditions: Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive; Melanoma; CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: dexamethasone; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Drug: bortezomib; Drug: vorinostat; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009 - Conditions: 714leukemia; Lymphoma
Intervention: Drug: Bortezomib (IV) and Everolimus (PO)
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI); The Leukemia and Lymphoma Society
Recruiting - verified December 2011 - Conditions: Graft vs Host Disease; Peripheral Blood Stem Cell Transplantation; Transplantation, Homologous
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Bortezomib
Sponsors: Indiana University; Indiana University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Neuroblastoma
Intervention: Drug: Irinotecan and Bortezomib
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified July 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab; Drug: Bortezomib; Drug: Lenalidomide
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Celgene Corporation
Recruiting - verified November 2011 - Conditions: Lymphoma, B-Cell; Follicular Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
Sponsors: Emory University; Emory University; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Bortezomib; Drug: Rituximab; Drug: Valacyclovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Mantle Cell Lymphoma; Lymphoma
Interventions: Drug: Bortezomib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Methotrexate; Drug: Cytarabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Drug: Carmustine; Drug: Cytarabine; Drug: Etoposide; Drug: Melphalan; Drug: Rituximab; Drug: Bortezomib; Other: Allogeneic Stem Cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Advanced Malignancy; Lymphoma; Myeloma; Solid Tumors
Interventions: Drug: Bevacizumab; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Relapsed Acute Leukemia; Refractory Acute Leukemia
Intervention: Drug: Bortezomib with mitoxantrone, etoposide and cytarabine
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaCondition: Lymphoma
Interventions: Drug: rituximab; Drug: bortezomib; Drug: Ibritumomab tiuxetan
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab; Drug: bortezomib
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified May 2012 - Condition: Renal Cell Cancer
Interventions: Drug: Bevacizumab and Bortezomib; Drug: Bevacizumab and Bortezomib
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012 - Condition: Lymphoma, Mantle Cell
Interventions: Drug: bortezomib; Other: clinical observation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Glioma
Interventions: Drug: Tamoxifen citrate; Drug: Bortezomib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm
Intervention: Drug: alvocidib + bortezomib
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified November 2011
 |
Bortezomib Clinical Trials |
